Krka Group 2025 Performance Estimate

The Management Board of Krka, d. d. held a press conference today to present the preliminary 2025 unaudited performance estimate for the Krka Group, which the Supervisory Board discussed at their meeting yesterday. The Krka Group generated revenue of €2,041.0 million, up €131.5 million or 7% on 2024. Earnings before interest, tax, depreciation and amortisation (EBITDA) amounted to €559.1 million, corresponding to 27.4% of total revenue. Net profit is projected at €401.1 million, up 13% year on year. Publication of the 2025 unaudited financial statements of the Krka Group and Krka is scheduled for Thursday, 12 March 2026.

The President of the Management Board and Chief Executive Jože Colarič explained: ‘This past year was a successful one. We have marked a notable milestone, outstripping €2 billion in revenue for the first time in history, and saw sales grow in most our markets, the highest in Region East Europe.

We are aware that long-term sales growth also depends on extension of the product portfolio, so we added 17 new products to it, and completed more than 900 marketing authorisation procedures for new and established products in various markets. Most of them are used for treating chronic cardiovascular and central nervous system diseases, gastrointestinal disorders, diabetes, and pain relief. They also include new combination medicines, which are gaining an ever more prominent share in Krka sales.

Sales growth led to increased profitability. We recorded estimated operating profit (EBIT) of €465.6 million, up 9%, and estimated net profit of €401.1 million, up €44.9 million or 13% on the year before. We remain committed to the course of our long‑term growth and development as set in the adopted Krka Group development strategy for the period until 2030. Our vertically integrated business model enables us to provide for uninterrupted supplies of sufficient quantities of high-quality, safe, and effective products, and deliver on our mission Living a healthy life. The adopted strategy also served as the basis for our 2026 business plan. The plan outlines revenue from sales of products and services at €2,132 million, net profit at €405 million, and almost a 50% increase in investments on the year before. We believe that with help of our committed coworkers already counting over 13,000 across the globe we will successfully deliver on all our plans.’

Krka Group performance estimates

Sales

The Krka Group generated €2,041.0 million in revenue last year. Of that, revenue from contracts with customers on sales of products and services amounted to €2,034.0 million, while other revenue from contracts with customers on sales of materials and other sales revenue constituted the difference. Revenue increased by €131.5 million or 7% on the year before. Sales increased in most markets.

Product and Service Sales by Region

      Region Slovenia,6.4
Region South-East Europe,14.3
Region East Europe,35.1
Region Central Europe,22.6
Region West Europe,17.9
Region Overseas Markets,3.7
    

Krka Group sales by product and service group

Sales of prescription pharmaceuticals totalled €1,691.7 million, up 8% on 2024, accounting for 83.2% of total Krka Group sales. We increased sales in all regions, except in Region Overseas Markets. Region East Europe increased sales by 12%; Region Central Europe and Region South-East Europe by 8% each; Region Slovenia by 6%; and Region West Europe by 4%. Of our ten largest individual markets, prescription pharmaceuticals saw the highest absolute sales growth in the Russian Federation, Poland, Scandinavia, and Germany. Of our other markets, sales increases were most substantial in Belarus, Belgium, and Portugal.

RELATED CONTENT

• Press release: 2025 Krka Group Performance Estimate (29. 1. 2026)